InMed Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (ZIP Code)
Registrant’s telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07: Submission of Matters to a Vote of Security Holders.
On December 17, 2025, InMed Pharmaceuticals Inc. (the "Corporation") held its 2025 Annual General and Special Meeting of Shareholders (the "Meeting"). At the Meeting, all items of business were voted upon by the shareholders, as indicated below:
Proposal No. 1-Presentation of Financial Statements
The Company's audited consolidated financial statements for the fiscal year ended June 30, 2025, including the related management's discussion and analysis and auditors report was presented to shareholders at the Meeting. No vote was taken with respect to the audited annual financial statements and receipt of the audited annual financial statements did not, and does not, constitute approval or disapproval of any matters referred to therein.
Proposal No. 2-Election of Directors
The Corporation's shareholders approved the election of five director nominees to the Corporation's board of directors (the "Board") to hold office until the 2026 Annual General Meeting of Shareholders or until their successors are elected or appointed.
Results of the vote for the election of the Board at the Meeting are set out as follows:
| Director | Votes For | Withheld Votes | ||||||||||
| Number | Percentage | Number | Percentage | |||||||||
| Eric A. Adams | 125,352 | 82.03% | 27,469 | 17.98% | ||||||||
| Andrew Hull | 125,315 | 82.00% | 27,506 | 18.00% | ||||||||
| Nicole Lemerond | 125,485 | 82.11% | 27,336 | 17.89% | ||||||||
| Neil Klompas | 125,444 | 82.09% | 27,377 | 17.91% | ||||||||
| John Bathery | 125,227 | 81.94% | 27,594 | 18.06% | ||||||||
Proposal No. 3-Appointment of Auditor
The Corporation's shareholders voted at the Meeting to approve the appointment of CBIZ CPAs P.C as the independent registered public accounting firm of the Corporation until the 2026 Annual General Meeting of Shareholders or until a successor is named.
| Votes For | % Votes For | Votes Against | Votes Abstained | % Votes Abstained1 | Broker Non-Votes |
| 783,232 | 78.84% | 0 | 210,258 | 21.16% | 1 |
Proposal No. 4-SEPA Share Issuance Proposal
Shareholders approved by ordinary resolution the potential issuance of 20% or more of the Corporation's common shares issued and outstanding as of December 13, 2024 pursuant to the Standby Equity Purchase Agreement with YA II PN, Ltd., as amended on June 13, 2025, pursuant to Nasdaq Listing Rules 5635(d) and 5635(b).
| Votes For | % Votes For | Vote Against | % Votes Against |
Abstain | Broker Non- Votes |
| 100,693 | 65.89% | 52,128 | 34.11% | 0 | 840,670 |
Proposal No. 5-Other Business
No other matters came to a vote before the Metting other than as set forth above.
| Votes For | % Votes For | Vote Against | % Votes Against | Abstain | Broker Non-Votes |
| 129,408 | 84.68% | 23,414 | 15.32% | 0 | 840,699 |
Item 7.01 Regulation FD Disclosure.
On December 18, 2024, the Corporation issued a press release announcing the voting results of the Meeting and other related matters. A copy of the press release is furnished hereto as Exhibit 99.1.
The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, including, without limitation, any registration statement filed pursuant thereto, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit 99.1. | Press release, dated December 17, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 17, 2025
| INMED PHARMACEUTICALS INC. |
||
| By: | /s/ Eric A. Adams | |
| Name: | Eric A. Adams | |
| Title: | Chief Executive Officer | |